Early induction of labour reduces shoulder dystocia rates in large for gestational age fetuses
1. Shoulder dystocia was less common in the early induction group compared to standard care. 2. Serious adverse events were...
Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
1. FDC obicetrapib plus ezetimibe significantly decreased LDL cholesterol levels by 48.6% compared to placebo. 2. Serious adverse events were...
Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes
1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events...
Oral gepotidacin is non-inferior to standard therapy for uncomplicated urogenital gonorrhea
1. Gepotidacin was non-inferior to ceftriaxone plus azithromycin for the primary outcome of microbiological success. 2. There were no serious...
Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation
1. Ischemic stroke occurred less often in patients with atrial fibrillation on DOACs compared to those on placebo. 2. Patients...
Atosiban does not improve neonatal outcomes in threatened preterm births between 30-34 weeks
1. Perinatal mortality and neonatal morbidity were comparable between the atosiban and placebo groups. 2. Maternal adverse events were similar...
Ivonescimab improves survival in advanced non-small cell lung cancer
1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade...
Exenatide does not slow Parkinson’s disease progression compared to placebo
1. There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and...
Ultrasound-guided radiofrequency ablation may be effective for treatment of aldosterone-producing adenomas
1. There were no gastric and adrenal puncture instances among patients who underwent radio-ablation in both groups. 2. Majority of...
Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer
1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events...
